European journal of breast health最新文献

{"title":"Primary Giant Cell Tumor of the Breast: Report of a Rare Case and Review of the Literature.","authors":"Sangeeta Pradhan, Meenakshi Rao, Sudeep Khera, Mahendra Lodha, Parmod Kumar, Taruna Yadav, Vinay N Gowda","doi":"10.4274/ejbh.galenos.2025.2025-2-9","DOIUrl":"10.4274/ejbh.galenos.2025.2025-2-9","url":null,"abstract":"<p><p>Primary giant cell tumors (GCTs) of soft tissue of the breast are extremely rare breast tumors, with only ten cases previously reported in the English literature. They are not suspected clinically, and clinically and histopathologically too, can mimic breast carcinoma or phyllodes tumor, and cause diagnostic dilemma. It is important to correctly recognize these tumors, due to management implications. Hereby, we present a case of 58 year old female with GCT of the breast presenting as a malignant breast tumor.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"387-388"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphedema and Axillary-Lateral Thoracic Vessel Juncture Irradiation: A Clinical Dilemma.","authors":"Şükran Şenyürek, Merve Duman, Sena Birsen Güçlü, Nilüfer Kılıç Durankuş, Duygu Sezen, Yasemin Bölükbaşı","doi":"10.4274/ejbh.galenos.2025.2025-2-8","DOIUrl":"10.4274/ejbh.galenos.2025.2025-2-8","url":null,"abstract":"<p><strong>Objective: </strong>Regional nodal irradiation (RNI) is one of the main causes of breast cancer-related lymphedema (BCRL). However, studies on the relationship between the radiation dose to the axillary-lateral thoracic vessel juncture (ALTJ) region and BCRL have reported conflicting results. Based on these findings, we aimed to evaluate the clinical relevance of the dose to the ALTJ region in our patient cohort.</p><p><strong>Materials and methods: </strong>Patients diagnosed with breast cancer and who were treated at Koç University Hospital between 2016 and 2022 and received RNI were included. BCRL was defined as a difference in arm circumference between the ipsilateral and contralateral limb >2.5 cm at any single encounter or ≥2 cm on ≥2 visits. ALTJ was retrospectively contoured, and doses were recorded as equivalent dose (α/β = 3).</p><p><strong>Results: </strong>Of the 129 patients (median age 49 years) who met the inclusion criteria, 12 (9.3%) had lymphedema. Two-thirds of the patients (66.7%) were stage II, and one-third (33.3%) were stage III. The median follow-up was 22 months. The median (range) ALTJ D_mean dose was 18.11 (1.87-50) Gy, the median ALTJ D_max was 44.53 (12.8-71.1) Gy, and the median ALTJ V35 was 38% (1-100%). No significant association was determined between ALTJ parameters and BCRL.</p><p><strong>Conclusion: </strong>There is insufficient data to define ALTJ as an OAR for decreasing BCRL risk. It is not appropriate to define dose and target based on ALTJ. Prospective studies with larger patient populations are needed to clarify the relationship between ALTJ and lymphedema.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"301-306"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reclassification of <i>BRCA1</i> and <i>BRCA2</i> Variants of Unknown Significance in a Turkish Cohort; A Single-Center, Retrospective Study.","authors":"Leyla Özer, Süleyman Aktuna, Evrim Ünsal","doi":"10.4274/ejbh.galenos.2025.2025-5-2","DOIUrl":"10.4274/ejbh.galenos.2025.2025-5-2","url":null,"abstract":"<p><strong>Objective: </strong>Accurate classification of <i>breast cancer susceptibility gene (BRCA)1/2</i> variants is important to delineate candidates for surgical or medical treatment. We retrospectively analyzed <i>BRCA1/BRCA2</i> sequencing data and reclassified the <i>BRCA1/2</i> variants of unknown significance (VUS) in Turkish patients with breast, ovarian, pancreatic and prostate cancers.</p><p><strong>Materials and methods: </strong><i>BRCA1/BRCA2</i> sequence data of a large cohort were retrospectively analyzed. The sequencing data were reinterpreted in the context of American College of Medical Genetics guidelines, the Evidence-based Network for the Interpretation of Germline Mutant Alleles <i>BRCA1/2</i> classification rules, and current public genomic databases.</p><p><strong>Results: </strong>Among the total of 2,713 patients, 254 (9.36%) had <i>BRCA1</i> or <i>BRCA2</i> variants. A total of 264 <i>BRCA1/BRCA2</i> variants were detected. Of these, 130 (49.2%) were pathogenic variants (PV), 24 (9%) were likely pathogenic (LP) and 110 of 264 variants (41.6%) were VUS. For the 119 <i>BRCA1</i> variants, 68% (<i>n</i> = 81) were PV, 7.5% (<i>n</i> = 9) were LP, and 24.5% (<i>n</i> = 29) were VUS. Similarly, for the 145 <i>BRCA2</i> variants, 33.7% (<i>n</i> = 49) were PV, 10.3% (<i>n</i> = 15) were LP, and 55.8% (<i>n</i> = 81) were VUS. Reanalysis of the 110 <i>BRCA1+BRCA2</i> VUS variants led to 22 (20%) being reclassified. Of these 22, 45.4% (<i>n</i> = 10) were reclassified as P/LP and 54.6% (<i>n</i> = 12) were reclassified as benign/likely benign.</p><p><strong>Conclusion: </strong>These results show that it may be possible to reclassify VUS, in this case <i>BRCA1/2</i> VUS, in light of changing genetic data. These results demonstrate the importance of VUS reclassification of <i>BRCA1/2</i> variants in clinical management, surgical decisions, risk counseling and screening.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"295-300"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between [¹⁸F]FDG PET/CT Texture Analysis and Progression-Free Survival in Patients Diagnosed With Invasive Breast Carcinoma.","authors":"Ogün Bülbül, Hande Melike Bülbül, Sibel Göksel","doi":"10.4274/ejbh.galenos.2025.2025-5-3","DOIUrl":"10.4274/ejbh.galenos.2025.2025-5-3","url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer is the most common cancer and the leading cause of cancer-related deaths in women. Texture analysis provides crucial prognostic information about many types of cancer, including breast cancer. The aim was to examine the relationship between texture features (TFs) of 2-deoxy-2[¹⁸F] fluoro-D-glucose positron emission tomography (PET)/computed tomography and disease progression in patients with invasive breast cancer.</p><p><strong>Materials and methods: </strong>TFs of the primary malignant lesion were extracted from PET images of 112 patients. TFs that showed significant differences between patients who achieved one-, three-, and five-year progression-free survival (PFS) and those who did not were selected and subjected to the least absolute shrinkage and selection operator regression method to reduce features and prevent overfitting. Machine learning (ML) was used to predict PFS using TFs and selected clinicopathological parameters.</p><p><strong>Results: </strong>In models using only TFs, random forest predicted one-, three-, and five-year PFS with area under the curve (AUC) values of 0.730, 0.758, and 0.797, respectively. Naive Bayes predicted one-, three-, and five-year PFS with AUC values of 0.857, 0.804, and 0.843, respectively. The neural network predicted one-, three-, and five-year PFS with AUC values of 0.782, 0.828, and 0.780, respectively. These findings indicated increased AUC values when the models combined TFs with clinicopathological parameters. The lowest AUC values of the models combining TFs and clinicopathological parameters when predicting one-year, three-year, and five-year PFS were 0.867, 0.898, and 0.867, respectively.</p><p><strong>Conclusion: </strong>ML models incorporating PET-derived TFs and clinical parameters may assist in predicting progression during the pre-treatment period in patients with invasive breast carcinoma.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"356-366"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Tissue Expression of HMBG1 Protein in Patients With Breast Cancer.","authors":"Gülden Diniz, İsmail Güzeliş, Dudu Solakoğlu Kahraman, Duygu Ayaz, Umut Varol, Mustafa Değirmenci","doi":"10.4274/ejbh.galenos.2025.2025-4-2","DOIUrl":"10.4274/ejbh.galenos.2025.2025-4-2","url":null,"abstract":"<p><strong>Objective: </strong>High mobility group box 1 (HMGB1) is a nonhistone chromatin-associated protein involved in chromatin remodeling, transcription, DNA replication, and repair. The purpose of this study was to assess the relationship between tissue expression of HMGB1, clinical outcomes, and histopathological characteristics in patients with breast cancer.</p><p><strong>Materials and methods: </strong>The study included 282 patients with breast cancer. An <i>in vitro</i> diagnostic HMGB1 antibody was applied to the slides of tumor specimens.</p><p><strong>Results: </strong>Overexpression of HMGB1 was found in tumor cells of 123 (43.6%) patients. HMGB1 was only expressed in the nucleus in most tumors (88.7%), while in 32 (11.3%) tumors HMBG1 expression was cytoplasmic and/or extracellular. Severe inflammatory infiltration of the peritumoral stroma was observed in 76 (27%) patients. There was a correlation between remarkable inflammatory cell infiltration in the tumor microenvironment and HMGB1 overexpression, regardless of the molecular subtype, as well as the extranuclear location of HMGB1 expression (<i>p</i> = 0.023). HMGB1 expression was not found to be associated with overall or disease-free survival. However, axillary lymph node metastasis was significantly more common in tumors with intense inflammation (<i>p</i> = 0.024).</p><p><strong>Conclusion: </strong>The proportion of breast cancer patients with HMGB1 expression was lower in the present study than that reported previously. Furthermore, we did not detect a relationship between HMGB1 expression and prognosis. However, the relationship between HMGB1 expression and prognosis had been previously reported only in aggressive breast cancers. It is suggested that understanding the significance of HMGB1 expression in breast cancer may open new treatment opportunities, especially in aggressive and/or triple negative tumors.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"290-294"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatofibrosarcoma Protuberans of the Breast.","authors":"Ramita Mukherjee, Rachana Meena, Brijesh Kumar Singh","doi":"10.4274/ejbh.galenos.2025.2025-3-13","DOIUrl":"10.4274/ejbh.galenos.2025.2025-3-13","url":null,"abstract":"<p><p>Dermatofibrosarcoma protuberans (DFSP) is a rare, low-grade, fibroblastic mesenchymal tumor derived from the dermis. Breast is an uncommon site with an incidence of only 0.8-4.5% and an overall population incidence at any site of 4.2-4.5 per million. Surgical excision with 2-3 cm margin is the gold standard treatment. Selected cases are subjected to radiotherapy or systemic therapy with Imatinib. Due to the rare presentation, we report a similar case of DFSP on the left breast in a 42-year-old woman, who was initially diagnosed with benign phyllodes tumor of the left breast and final histopathology report of the wide local excision specimen diagnosed DFSP of the breast.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"389-391"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144823475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Body Image Satisfaction in Post-Mastectomy Female Breast Cancer Patients.","authors":"Rija Latifee, Usra Parvez, Shah Muhammad, Bushra Shirazi, Muhammad Arsalan Khan","doi":"10.4274/ejbh.galenos.2025.2025-5-7","DOIUrl":"10.4274/ejbh.galenos.2025.2025-5-7","url":null,"abstract":"<p><strong>Objective: </strong>Mastectomy is a widely used surgical intervention for breast cancer in Pakistan, where late-stage diagnoses are common and breast-conserving options are often limited. While effective oncologically, mastectomy can significantly affect a woman's body image, emotional well-being, and social relationships. In Pakistan, sociocultural norms and limited reconstructive services further shape the post-mastectomy experience. This study aimed to assess self-perception, body image satisfaction, and related psychosocial impact in Pakistani women following mastectomy.</p><p><strong>Materials and methods: </strong>This descriptive cross-sectional study was conducted at the breast oncology clinic of the Sindh Institute of Urology and Transplantation, Karachi. A total of 159 post-mastectomy patients aged 18-65 years were surveyed using a structured, culturally adapted questionnaire based on the body image scale. Statistical analyses included chi-square testing and multinomial logistic regression to assess associations between body image perception and demographic or psychosocial variables. Internal consistency was confirmed (Cronbach's alpha = 0.863).</p><p><strong>Results: </strong>While 34% reported no change in body image perception, 66% reported varying degrees of change. Strong associations were identified between negative body image perception and feelings of reduced attractiveness, mirror discomfort, and spousal relationship changes (p<0.001). Multinomial regression confirmed these as significant predictors of reporting major body image change. Interest in breast reconstruction was low (15.7%), and although age and education were not significantly associated, time since surgery approached significance (<i>p</i> = 0.07).</p><p><strong>Conclusion: </strong>A substantial proportion of Pakistani women experience emotional and psychosocial distress following mastectomy. These findings highlight the importance of early counseling, spousal support, and culturally sensitive body image discussions to promote long-term psychosocial recovery.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"326-332"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of Intraoperative Sentinel Lymph Node Evaluation by Imprint Cytology in Breast Cancer: A 12-Year Single Center Experience With 2,528 Patients.","authors":"Aysel Bayram, Sidar Bagbudar, Cagla Safak Karaoglan, Esma Sayar, Baran Mollavelioglu, Mustafa Tukenmez, Hasan Karanlık, Semen Onder, Ekrem Yavuz","doi":"10.4274/ejbh.galenos.2025.2025-5-10","DOIUrl":"10.4274/ejbh.galenos.2025.2025-5-10","url":null,"abstract":"<p><strong>Objective: </strong>Sentinel lymph node biopsy (SLNB) is a key procedure for evaluating axillary lymph node status in early breast cancer, offering lower morbidity than axillary lymph node dissection. Intraoperative evaluation (IOE) of sentinel lymph nodes (SLNs) with methods like frozen section (FS) and imprint cytology (IC) aid in making immediate surgical decisions, although IOE accuracy may vary due to several factors.</p><p><strong>Materials and methods: </strong>This retrospective study involved 2,528 patients with invasive breast cancer who underwent SLNB at a single institution from 2012 to 2024. Primarily, IC was used for intraoperative assessment, while FS was selectively performed in certain cases, such as with suspicious macroscopic findings or after neoadjuvant chemotherapy (NAC). The final diagnosis relied on permanent sections with serial step-leveling and classification of metastasis size.</p><p><strong>Results: </strong>IOE showed a sensitivity of 65.8% and specificity of 97% for detecting lymph node metastases. The combination of IC and FS yielded higher sensitivity (76.1%) compared to IC alone (64.1%), particularly for isolated tumor cells (ITC). Patients treated with NAC exhibited slightly lower IOE accuracy (83.8%) compared to those without NAC (85.9%). False negatives were more common in cases of micrometastasis, ITC, and invasive lobular subtype. Excluding micrometastasis and ITC significantly enhanced IOE accuracy.</p><p><strong>Conclusion: </strong>The accuracy of intraoperative SLN evaluation is affected by size of the metastasis, tumor subtype, and prior NAC. While IC is acceptable for IOE, combining IC and FS is advised, especially in the setting of earlier NAC, to enhance accuracy for small metastatic foci.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"333-338"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemochromatosis: A Risk Factor for Breast Cancer? Systematic Review and Meta-Analysis.","authors":"Megane Buttignol, Caroline Bouche, Manon Chrétien, Nicolas Taris, Tolga Ozmen, Carole Mathelin","doi":"10.4274/ejbh.galenos.2025.2025-7-1","DOIUrl":"10.4274/ejbh.galenos.2025.2025-7-1","url":null,"abstract":"<p><strong>Objective: </strong>Hereditary hemochromatosis and breast cancer are two major public health problems. The <i>HFE</i> gene variants C282Y and H63D, responsible for most cases of hemochromatosis, may contribute to carcinogenesis via iron overload, oxidative stress, and hormonal modulation. The aim of this study was to evaluate the association between <i>HFE</i> variants and breast cancer risk and propose a personalized surveillance strategy.</p><p><strong>Materials and methods: </strong>A systematic review and a meta-analysis were conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible studies included case-control and cohort studies reporting breast cancer incidence in women with <i>HFE</i> gene C282Y and/or H63D variants. Data were pooled using a random-effects model. Subgroup analyses and meta-regressions explored sources of heterogeneity.</p><p><strong>Results: </strong>Eight studies comprising 73,981 participants were included, published between 2000 and 2025. Among them, analysis of four revealed a link between hemochromatosis and breast cancer risk. In one study, a link was observed between the <i>HFE</i> C282Y allele and higher lymph node involvement, which may suggest an impact of hemochromatosis on tumor progression. By contrast, three studies did not find any link between the two diseases. Our meta-analysis showed a trend toward increased breast cancer risk in carriers of <i>HFE</i> variants, particularly C282Y homozygotes (odds ratio = 1.36, 95% confidence interval = 0.75-1.98). Substantial heterogeneity was present (I² >50%), but no tested covariates significantly explained this variation. Sensitivity analyses confirmed the robustness of the estimate.</p><p><strong>Conclusion: </strong>In the absence of randomized trials with mortality endpoints, our findings do not yet justify changes in clinical practice. They nevertheless support prospective studies to assess whether women carrying these pathogenic variants, especially C282Y/C282Y homozygotes, could benefit from adapted breast cancer surveillance, potentially involving more frequent evaluations or advanced imaging to improve early detection.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"367-374"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on the \"Breast Imaging: Correlation Between Axillary Lymph Nodes Apparent Diffusion Coefficient and Pathological Lymphovascular Invasion in Patients With Invasive Breast Cancer\".","authors":"Ahmet Bozer","doi":"10.4274/ejbh.galenos.2025.2025-3-12","DOIUrl":"10.4274/ejbh.galenos.2025.2025-3-12","url":null,"abstract":"","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"392-393"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}